Biogen (NASDAQ:BIIB – Get Free Report) had its price target lifted by Wedbush from $201.00 to $215.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 4.39% from the company’s previous close.
Several other equities research analysts also recently issued reports on the company. HSBC restated a “reduce” rating and set a $157.00 target price on shares of Biogen in a research report on Monday, July 6th. Zacks Research upgraded Biogen from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Wall Street Zen raised Biogen from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Freedom Capital upgraded Biogen from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 1st. Finally, Sanford C. Bernstein reduced their target price on Biogen from $201.00 to $200.00 in a report on Thursday, April 30th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $221.61.
Get Our Latest Stock Analysis on BIIB
Biogen Stock Performance
Biogen (NASDAQ:BIIB – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same period last year, the firm earned $5.47 EPS. Biogen’s revenue for the quarter was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Sell-side analysts predict that Biogen will post 11.28 earnings per share for the current year.
Institutional Investors Weigh In On Biogen
Several large investors have recently added to or reduced their stakes in BIIB. LSV Asset Management lifted its position in Biogen by 3.3% during the fourth quarter. LSV Asset Management now owns 316,815 shares of the biotechnology company’s stock valued at $55,756,000 after purchasing an additional 9,976 shares during the last quarter. Catalyst Funds Management Pty Ltd bought a new position in shares of Biogen in the 4th quarter worth $2,006,000. Orbimed Advisors LLC purchased a new stake in shares of Biogen during the 1st quarter valued at $11,293,000. Systematic Financial Management LP raised its position in shares of Biogen by 256.3% during the 4th quarter. Systematic Financial Management LP now owns 16,640 shares of the biotechnology company’s stock valued at $2,928,000 after buying an additional 11,970 shares in the last quarter. Finally, Contrarius Group Holdings Ltd bought a new stake in shares of Biogen during the 4th quarter worth $11,431,000. Institutional investors own 87.93% of the company’s stock.
Key Stories Impacting Biogen
Here are the key news stories impacting Biogen this week:
- Positive Sentiment: Biogen reported second-quarter revenue of $2.74 billion, up 3.4% year over year and above the approximately $2.46 billion consensus estimate. Adjusted EPS of $3.60 also exceeded expectations near $2.94, helped by strong demand for rare-disease treatments and the company’s growth portfolio. Reuters article
- Positive Sentiment: The growth portfolio generated roughly $1.06 billion in quarterly revenue, up 24% year over year and exceeding sales from Biogen’s legacy multiple sclerosis portfolio. SKYCLARYS, ZURZUVAE, and products acquired through the Apellis transaction contributed to the improved mix. Seeking Alpha article
- Positive Sentiment: Management raised its 2026 revenue expectations to mid-single-digit growth and pointed to pipeline progress, including Alzheimer’s-related developments, reinforcing the potential for a longer-term turnaround. Needham reiterated its Buy rating and maintained a $256 price target. TipRanks article
- Neutral Sentiment: Zacks Research upgraded Biogen (BIIB) from “Strong Sell” to “Hold,” signaling improved sentiment but not a bullish recommendation. Zacks.com
- Negative Sentiment: Biogen’s reported profit fell sharply from the prior year, while full-year non-GAAP EPS guidance of $12 to $13 remains below the roughly $13.45 consensus estimate. Legacy multiple sclerosis products also continued to decline, and Leqembi sales narrowly missed expectations. Wall Street Journal article
Biogen Company Profile
Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.
The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.
Featured Articles
- Five stocks we like better than Biogen
- 2 Unique Space ETFs That Could Upend the Industry
- Corning Stock Crashes on Earnings, But the Sell-Off Looks Overdone
- Palantir’s Earnings Setup Puts Its AI Growth Story Back on Trial Again
- Mining For Megawatts: AMD’s Billion-Dollar Grid Grab
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
